Inactive Instrument

Ibex Technologies

Equities

IBT

CA4489375085

IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024

December 14, 2023 at 01:00 pm

IBEX Technologies Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenues to be in the fiscal year 2023 range, with continued strong growth in the hemostasis business. Earnings before tax to be in line with the fiscal year 2023.

Latest news about Ibex Technologies

IBEX Completes C$37.9-Million Sale Of the Company	04-08	MT
BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others.	04-07	CI
IBEX Shareholders Approve the C$37.9-Million Sale of Company	04-03	MT
Refile: IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024	03-25	MT
IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024	03-25	MT
IBEX Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	03-22	CI
IBEX Reports Results For The Second Quarter And Six Months Ending January 31, 2024	03-22	MT
IBEX Technologies Issues Management Circular Ahead of Vote of C$37.9-Million Acquisition Offer	02-23	MT
IBEX Technologies Signs Definitive Agreement to Sell Company for $1.45 Cash Per Share	02-12	MT
15720273 Canada Inc. entered into a binding acquisition agreement to acquire IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million.	02-11	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	12-14	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on July 17, 2023.	12-14	CI
IBEX Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	12-14	CI
IBEX Technologies Inc. Provides Earnings Guidance for the Fiscal Year 2024	12-14	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	11-09	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on July 17, 2023.	11-09	CI
IBEX Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	11-09	CI
IBEX Technologies Inc.'s Equity Buyback announced on August 2, 2022, has expired with 64,600 shares, representing 0.26% for CAD 0.04 million.	03/08/23	CI
IBEX Technologies Renews Normal Course Issuer Bid	17/07/23	MT
IBEX Technologies Inc. announces an Equity Buyback for 1,500,000 shares, representing 6.06% of its issued share capital.	17/07/23	CI
IBEX Technologies Inc. authorizes a Buyback Plan.	16/07/23	CI
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	07/06/23	CI
IBEX Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	07/06/23	CI
IBEX Technologies Fiscal Q2 Profit Falls 75% on Weaker Sales	20/03/23	MT
Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	20/03/23	CI

Chart Ibex Technologies

Duration

Period

More charts

Company Profile

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.âs primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISAâs) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.

Sector

More about the company